|
1
|
Gale M Jr and Foy EM: Evasion of
intracellular host defense by hepatitis C virus. Nature.
436:939–945. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Borden EC, Sen GC, Uze G, Silverman RH,
Ransohoff RM, Foster GR and Stark G: Interferons at age 50: Past,
current and future impact on biomedicine. Nat Rev Drug Discov.
6:975–990. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weber F: Interaction of hepatitis C virus
with type I interferon system. World J Gastroenterol. 13:4818–4823.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fried MW, Shiffman ML, Reddy KR, Smith C,
Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G,
Dhumeaux D, et al: Peginterferon alfa-2a plus ribavirin for chronic
hepatitis C virus infection. N Engl J Med. 347:975–982. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Manns MP, McHutchison JG, Gordon SC,
Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M
and Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with
interferon alfa-2b plus ribavirin for initial treatment of chronic
hepatitis C: A randomised trial. Lancet. 358:958–965. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marrache F, Consigny Y, Ripault MP,
Cazals-Hatem D, Martinot M, Boyer N, Degott C, Valla D and
Marcellin P: Safety and efficacy of peginterferon plus ribavirin in
patients with chronic hepatitis C and bridging fibrosis or
cirrhosis. J Viral Hepat. 12:421–428. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Everson GT, Hoefs JC, Seeff LB, Bonkovsky
HL, Naishadham D, Schiffman ML, Kahn JA, Lok ASF, Di Bisceglie AM,
Lee WM, et al: Impact of disease severity on outcome of antiviral
therapy for chronic hepatitis C: Lessons from the HALT-C trial.
Hepatology. 44:1675–1684. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bruno S, Shiffman ML, Roberts SK, Gane EJ,
Messinger D, Hadziyannis SJ and Marcellin P: Efficacy and safety of
peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients
with advanced fibrosis and cirrhosis. Hepatology. 51:388–397. 2010.
View Article : Google Scholar
|
|
9
|
Cheng WS, Roberts SK, McCaughan G, Sievert
W, Weltman M, Crawford D, Rawlinson W, Marks PS, Thommes J,
Rizkalla B, et al: Low virological response and high relapse rates
in hepatitis C genotype 1 patients with advanced fibrosis despite
adequate therapeutic dosing. J Hepatol. 53:616–623. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Asselah T, Estrabaud E, Bieche I, Lapalus
M, De Muynck S, Vidaud M, Saadoun D, Soumelis V and Marcellin P:
Hepatitis C: Viral and host factors associated with non-response to
pegylated interferon plus ribavirin. Liver Int. 30:1259–1269. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jacobson IM, McHutchison JG, Dusheiko G,
Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci
P, Flisiak R, et al: Telaprevir for previously untreated chronic
hepatitis C virus infection. N Engl J Med. 364:2405–2416. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bruno S, Vierling JM, Esteban R, Nyberg
LM, Tanno H, Goodman Z, Poordad F, Bacon B, Gottesdiener K,
Pedicone LD, et al: Efficacy and safety of boceprevir plus
peginterferon-ribavirin in patients with HCV G1 infection and
advanced fibrosis/cirrhosis. J Hepatol. 58:479–487. 2013.
View Article : Google Scholar
|
|
13
|
Liang TJ and Ghany MG: Current and future
therapies for hepatitis C virus infection. N Engl J Med.
368:1907–1917. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Casey LC and Lee WM: Hepatitis C virus
therapy update 2013. Curr Opin Gastroenterol. 29:243–249.
2013.PubMed/NCBI
|
|
15
|
Shah N, Pierce T and Kowdley KV: Review of
directacting antiviral agents for the treatment of chronic
hepatitis C. Expert Opin Investig Drugs. 22:1107–1121. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meissner EG, Wu D, Osinusi A, Bon D,
Virtaneva K, Sturdevant D, Porcella S, Wang H, Herrmann E,
McHutchison J, et al: Endogenous intrahepatic IFNs and association
with IFN-free HCV treatment outcome. J Clin Invest. 124:3352–3363.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Friedman SL: Mechanisms of hepatic
fibrosis. Gastroenterology. 134:1655–1669. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Inagaki Y and Okazaki I: Emerging insights
into transforming growth factor beta Smad signal in hepatic
fibrogenesis. Gut. 56:284–292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hynes RO: Integrins: Bidirectional,
allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hehlgans S, Hasse M and Cordes N:
Signalling via integrins: Implications for cell survival and
anticancer strategies. Biochem Biophys Acta. 1775:163–180.
2017.
|
|
21
|
Millard M, Odde S and Neamati N: Integrin
targeted therapeutics. Thearanostics. 1:154–188. 2011. View Article : Google Scholar
|
|
22
|
Hayashida T: Integrins modulate cellular
fibrogenesis at multiple levels; Regulation of TGF-β signaling.
Endocr Metab Immune Disord Drug Targets. 10:302–319. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ikeda M, Abe K, Dansako H, Nakamura T,
Naka K and Kato N: Efficient replication of a full-length hepatitis
C virus genome, strain O, in cell culture, and development of a
luciferase reporter system. Biochem Biophys Res Commun.
329:1350–1359. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ozaki I, Zhang H, Mizuta T, Ide Y, Eguchi
Y, Yasutake T, Sakamaki T, Pestell RG and Yamamoto K:
Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular
carcinoma cell growth by suppressing cyclin D1 expression through
inhibition of nuclear factor kappaB activation. Clin Cancer Res.
13:2236–2245. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang B, Trippler M, Pei R, Lu M, Broering
R, Gerken G and Schlaak JF: Toll-like receptor activated human and
murine hepatic stellate cells are potent regulators of hepatitis C
virus replication. J Hepatol. 51:1037–1045. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Y, Li J, Wang X, Ye L, Zhou Y and Ho
W: Induction of interferon-λ contributes to Toll-like
receptor-3-activated hepatic stellate cell-mediated hepatitis C
virus inhibition in hepatocytes. J Viral Hepat. 20:385–394. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alisi A, Arciello M, Petrini S, Conti B,
Missale G and Balsano C: Focal adhesion kinase (FAK) mediates the
induction of pro-oncogenic and fibrogenic phenotypes in hepatitis C
virus (HCV)-infected cells. PLoS One. 7:e441472012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu X and Assoian RK: Integrin-dependent
activation of MAP kinase: A link to shape-dependent cell
proliferation. Mol Biol Cell. 6:273–282. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Khwaja A, Rodriguez-Viciana P, Wennström
S, Warne PH and Downward J: Matrix adhesion and Ras transformation
both activate a phosphoinositide 3-OH-kinase and protein kinase
B/Akt cellular survival pathway. EMBO J. 16:2783–2793. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang H, Ozaki I, Mizuta T, Yoshimura T,
Matsuhashi S, Eguchi Y, Yasutake T, Hisatomi A, Sakai T and
Yamamoto K: Transforming growth factor-beta 1-induced apoptosis is
blocked by beta 1-integrin-mediated mitogen-activated protein
kinase activation in human hepatoma cells. Cancer Sci. 95:878–886.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yau CY, Wheeler JJ, Sutton KL and Hedley
DW: Inhibition of integrin-linked kinase by a selective small
molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and
FKHR pathways and tumor growth, and enhances gemcitabine-induced
apoptosis in human orthotopic primary pancreatic cancer xenografts.
Cancer Res. 65:1497–1504. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Riaz A, Ilan N, Vlodavsky I, Li JP and
Johansson S: Characterization of heparanase-induced
phosphatidylinositol 3-kinase-AKT activation and its integrin
dependence. J Biol Chem. 288:12366–12375. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Garamszegi N, Garamszegi SP,
Samavarchi-Tehrani P, Walford E, Schneiderbauer MM, Wrana JL and
Scully SP: Extracellular matrix-induced transforming growth
factor-beta receptor signaling dynamics. Oncogene. 29:2368–2380.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ozaki I, Hamajima H, Matsuhashi S and
Mizuta T: Regulation of TGF-β1-induced pro-apoptotic signaling by
growth factor receptors and extracellular matrix receptor integrins
in the liver. Front Physiol. 2:782011. View Article : Google Scholar
|
|
35
|
Shirasaki T, Honda M, Shimakami T, Murai
K, Shiomoto T, Okada H, Takabatake A, Tokumaru A, Sakai Y,
Yamashita T, et al: Impaired interferon signaling in chronic
hepatitis C patients with advanced fibrosis via the transforming
growth factor beta signaling pathway. Hepatology. 60:1519–1530.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang D, Zhou GH, Birkenmeier TM, Gong J,
Sun L and Brattain MG: Autocrine transforming growth factor beta-1
modulates the expression of integrin alpha 5 beta1 in human colon
carcinoma FET cells. J Biol Chem. 270:14154–14159. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kaur S, Sassano A, Dolniak B, Joshi S,
Majchrzak-Kita B, Baker DP, Hay N, Fish EN and Platanias LC: Role
of the Akt pathway in mRNA translation of interferon-stimulated
genes. Proc Natl Acad Sci USA. 105:4808–4813. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lekmine F, Uddin S, Sassano A, Parmar S,
Brachmann SM, Majchrzak B, Sonenberg N, Hay N, Fish EN and
Platanias LC: Activation of the p70 S6 kinase and phosphorylation
of the 4E-BP1 repressor of mRNA translation by type I interferons.
J Biol Chem. 278:27772–27780. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zeller KS, Idevall-Hagren O, Stefansson A,
Velling T, Jackson SP, Downward J, Tengholm A and Johansson S:
PI3-kinase 110α mediates β1 integrin-induced Akt activation and
membrane protrusion during cell attachment and initial spreading.
Cell Signal. 22:1838–1848. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tang Q, Zhao S, Wu J, Zheng F, Yang L, Hu
J and Hann SS: Inhibition of integrin-linked kinase expression by
emodin through crosstalk of AMPKα and ERK1/2 signaling and
reciprocal interplay of Sp1 and c-Jun. Cell signaling.
27:1469–1477. 2015. View Article : Google Scholar
|
|
41
|
Hirata E, Girotti MR, Viros A, Hooper S,
Spencer-Dene B, Matsuda M, Larkin J, Marais R and Sahai E:
Intravital imaging reveals how BRAF inhibition generates
drug-tolerant microenvironments with high integrin β1/FAK
signaling. Cancer Cell. 27:574–588. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Asahina Y, Tsuchiya K, Tamaki N, Hirayama
I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda K, Kuzuya T, et al:
Effect of aging on risk for hepatocellular carcinoma in chronic
hepatitis C virus infection. Hepatology. 52:518–527. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Morgan RL, Baack B, Smith BD, Yartel A,
Pitasi M and Falck-Ytter Y: Eradication of hepatitis C virus
infection and the development of hepatocellular carcinoma: A
meta-analysis of observational studies. Ann Intern Med.
158:329–337. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang DY and Friedman SL:
Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology.
56:769–775. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zitvogel L, Galluzzi L, Kepp O, Smyth MJ
and Kroemer G: Type I interferons in anticancer immunity. Nat Rev
Immunol. 15:405–414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yano H, Iemura A, Haramaki M, Ogasawara S,
Takayama A, Akiba J and Kojiro M: Interferon alfa receptor
expression and growth inhibition by interferon alfa in human liver
cancer cell lines. Hepatology. 29:1708–1717. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kusano H, Akiba J, Ogasawara S, Sanada S,
Yasumoto M, Nakayama M, Ueda K, Ueda K, Kurita T, Todoroki K, et
al: Pegylated interferon-α2a inhibits proliferation of human liver
cancer cells in vitro and in vivo. PLoS One. 8:e831952013.
View Article : Google Scholar
|
